title: Cytotoxic T lymphocytes for leukemia and lymphoma.
abstract: This chapter focuses on the recent advances in adoptive T-cell immunotherapies, not only for patients after hematopoietic stem cell transplantation, but also in the autologous setting using T cells early in the disease process for the treatment of the highest-risk patients with leukemias and lymphomas. The particular emphasis is to highlight the role of T-cell therapies for hematologic malignancies using a non-gene-transfer approach to direct specificity, including the clinical use of T-cell therapies for EBV-associated lymphomas and strategies for targeting nonviral lymphoma- and leukemia-associated antigens.
authors.affiliation: Children's National Health System and The George Washington University, Washington, DC; and.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.affiliation: National Heart, Lung, and Blood Institute, National Institutes for Health, Bethesda, MD.
authors.forename: A John
authors.initials: AJ
authors.lastname: Barrett
mesh_terms: D002450:Cell Communication / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007938:Leukemia / Q000276:immunology* / Q000628:therapy; D008223:Lymphoma / Q000276:immunology* / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016896:Treatment Outcome